AU2016383376B2 - Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease - Google Patents

Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease Download PDF

Info

Publication number
AU2016383376B2
AU2016383376B2 AU2016383376A AU2016383376A AU2016383376B2 AU 2016383376 B2 AU2016383376 B2 AU 2016383376B2 AU 2016383376 A AU2016383376 A AU 2016383376A AU 2016383376 A AU2016383376 A AU 2016383376A AU 2016383376 B2 AU2016383376 B2 AU 2016383376B2
Authority
AU
Australia
Prior art keywords
fatty liver
liver disease
triacetyl
alcoholic fatty
hydroxyphenyladenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016383376A
Other languages
English (en)
Other versions
AU2016383376A1 (en
Inventor
Huijie SHI
Haibo Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Gushen Life Health Technology Co Ltd
Institute of Materia Medica of CAMS and PUMC
Original Assignee
Beijing Gushen Life Health Technology Co Ltd
Institute of Materia Medica of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Gushen Life Health Technology Co Ltd, Institute of Materia Medica of CAMS and PUMC filed Critical Beijing Gushen Life Health Technology Co Ltd
Publication of AU2016383376A1 publication Critical patent/AU2016383376A1/en
Assigned to INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES, Beijing Gushen Life Health Technology Co., Ltd reassignment INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES Request for Assignment Assignors: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES, JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.
Application granted granted Critical
Publication of AU2016383376B2 publication Critical patent/AU2016383376B2/en
Assigned to INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES, Beijing Gushen Life Health Technology Co., Ltd. reassignment INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES Amend patent request/document other than specification (104) Assignors: Beijing Gushen Life Health Technology Co., Ltd, INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2016383376A 2015-12-31 2016-12-28 Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease Active AU2016383376B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201511034199 2015-12-31
CN201511034199.0 2015-12-31
PCT/CN2016/112623 WO2017114413A1 (zh) 2015-12-31 2016-12-28 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Publications (2)

Publication Number Publication Date
AU2016383376A1 AU2016383376A1 (en) 2018-07-12
AU2016383376B2 true AU2016383376B2 (en) 2022-07-28

Family

ID=59224622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016383376A Active AU2016383376B2 (en) 2015-12-31 2016-12-28 Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease

Country Status (11)

Country Link
US (1) US11058703B2 (enExample)
EP (1) EP3398604A4 (enExample)
JP (1) JP7382716B2 (enExample)
KR (1) KR102676056B1 (enExample)
CN (2) CN106943420A (enExample)
AU (1) AU2016383376B2 (enExample)
CA (1) CA3010097C (enExample)
HK (1) HK1255689A1 (enExample)
RU (1) RU2759916C2 (enExample)
WO (1) WO2017114413A1 (enExample)
ZA (1) ZA201805080B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
KR20210016407A (ko) * 2018-06-05 2021-02-15 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 대사 장애 및 비알코올성 지방 간 질환의 치료를 위한 활성제 및 그 사용 방법
CN111821313A (zh) * 2019-04-17 2020-10-27 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备抑制心脏纤维化的药物中的应用
CN114869901B (zh) * 2022-05-06 2023-10-27 安徽医科大学 马鞭草苷在治疗酒精性肝损伤药物中的应用
CN117599076A (zh) * 2023-11-15 2024-02-27 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874036A (zh) * 2008-10-06 2010-10-27 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132812A (ja) 2003-10-08 2005-05-26 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物の分画物およびその用途
CN100427534C (zh) * 2004-03-19 2008-10-22 四川大学 聚合物型含磷阻燃剂及其制备方法和用途
JP2007210926A (ja) 2006-02-08 2007-08-23 Tokyo Univ Of Pharmacy & Life Science ピラジンカルボン酸化合物からなる薬剤、及び食餌
JP5688229B2 (ja) 2010-03-19 2015-03-25 国立大学法人名古屋大学 肝保護作用を有するタンパク質、肝障害予防・保護用化合物のスクリーニング方法
CN102125580A (zh) * 2011-01-17 2011-07-20 泰山医学院 三乙酰基-3-羟基苯基腺苷thpa在制药中的应用
ME02312B (me) * 2011-04-22 2016-06-20 Pfizer DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
AU2013204500A1 (en) 2012-09-21 2014-04-10 Barbara Jane Badenoch-Jones Novel AMPK agonist compositions and methods of use
CN103191145A (zh) 2013-03-27 2013-07-10 南京理工大学 腺苷及其衍生物在防治药物性肝损伤中的应用
CN104211747B (zh) * 2013-05-29 2018-09-25 中国医学科学院药物研究所 5’-磷酸-n6-（3-羟基苯基）腺苷的制备及医药用途
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
CN104546887B (zh) * 2013-10-09 2018-10-30 中国医学科学院药物研究所 虫草素衍生物治疗炎症疾病的用途
CN105663152A (zh) 2014-11-19 2016-06-15 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874036A (zh) * 2008-10-06 2010-10-27 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIAN, Zequin, et al., LIPIDS IN HEALTH AND DISEASE, (2011), 10:67 *

Also Published As

Publication number Publication date
JP7382716B2 (ja) 2023-11-17
US20190022120A1 (en) 2019-01-24
CA3010097C (en) 2023-08-22
KR20180100152A (ko) 2018-09-07
RU2018126158A (ru) 2020-01-31
AU2016383376A1 (en) 2018-07-12
EP3398604A1 (en) 2018-11-07
CN106943420A (zh) 2017-07-14
US11058703B2 (en) 2021-07-13
JP2019500379A (ja) 2019-01-10
KR102676056B1 (ko) 2024-06-19
RU2018126158A3 (enExample) 2020-03-11
CA3010097A1 (en) 2017-07-06
ZA201805080B (en) 2019-10-30
EP3398604A4 (en) 2019-06-19
WO2017114413A1 (zh) 2017-07-06
CN118178446A (zh) 2024-06-14
RU2759916C2 (ru) 2021-11-18
HK1255689A1 (en) 2019-08-23

Similar Documents

Publication Publication Date Title
AU2016383376B2 (en) Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
US11903932B2 (en) Use of dihydroberberine or its derivatives to enhance muscle function
EP2147671A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
CN118234493A (zh) 包含wee1抑制剂和dna损伤反应(ddr)抑制剂的组合疗法
KR20220157313A (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
CN117599036A (zh) 隐绿原酸在制备治疗和/或预防非酒精性脂肪肝产品中的用途
US20210196737A1 (en) Use of trezastilbenoside in manufacture of product for treating and/or preventing non-alcoholic fatty liver disease
WO2025103336A1 (zh) 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用
CN107737136A (zh) 一种药物组合物在预防和/或治疗高脂血症与降血糖中的用途
CN107334775A (zh) 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
CN106727480B (zh) Fex-3在制备抗肥胖症药物中的应用
CN111686239B (zh) 抗真菌化合物的应用
TW202239401A (zh) 正丁基苯酞於促進脂肪褐變、以及預防或治療脂肪肝及相關肝病變之應用
CN103735549A (zh) 盐酸去亚甲基小檗碱在制备治疗非酒精性脂肪肝病药物中的应用
CN106943408B (zh) 四甲基尿酸预防和治疗糖尿病的应用
CN111000852A (zh) 苦蘵中睡茄内酯提取物在制备预防或治疗非酒精性脂肪性肝病的药物中应用
CN117100739B (zh) 负调节Nrf2信号通路的小分子组合物及其应用
KR101613252B1 (ko) 아르기나아제 억제제를 함유하는 비만 및 지방간 예방 또는 치료용 조성물
KR20080094466A (ko) 대사증후군 치료용 약제 조성물
CN103550211A (zh) 盐酸小檗碱在制备预防和/或治疗急慢性酒精性肝病药物中的应用
CN113368107B (zh) 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途
CN117137916A (zh) 盐酸去亚甲基小檗碱在制备预防或治疗银屑病药物的应用
CN117085020A (zh) 可可碱在制备治疗和/或预防脂质代谢异常相关疾病药物中的应用
CN116747226A (zh) 黄柏碱在制备治疗和/或预防非酒精性脂肪肝炎药物中的应用
CN114903894A (zh) Magl抑制剂抗非酒精性脂肪肝病的用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Free format text: FORMER APPLICANT(S): JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.; INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Owner name: BEIJING GUSHEN LIFE HEALTH TECHNOLOGY CO., LTD

Free format text: FORMER APPLICANT(S): JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.; INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

HB Alteration of name in register

Owner name: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Free format text: FORMER NAME(S): BEIJING GUSHEN LIFE HEALTH TECHNOLOGY CO., LTD ; INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Owner name: BEIJING GUSHEN LIFE HEALTH TECHNOLOGY CO., LTD.

Free format text: FORMER NAME(S): BEIJING GUSHEN LIFE HEALTH TECHNOLOGY CO., LTD ; INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

FGA Letters patent sealed or granted (standard patent)